Multifunctional Biomimetic Nanocarriers for Dual‐Targeted Immuno‐Gene Therapy Against Hepatocellular Carcinoma
Advanced Science · 2024
DOI: 10.1002/advs.202400951 ↗Kurz gefasst
Fachartikel in der Zeitschrift Advanced Science, 2024. Verfasst von Yupeng Sun und 12 weiteren Autor:innen. Beteiligte Einrichtung: The United Innovation of Mengchao Hepatobiliary Technology Key Laboratory of Fujian Province, Mengchao Hepatobiliary Hospital of Fujian Medical Unive…. Hauptthemen laut MEDLINE: Immunotherapy, Liver Neoplasms, Carcinoma, Hepatocellular, Genetic Therapy. Die Arbeit wurde bisher 14-mal zitiert (Crossref) und nennt 54 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: National Natural Science Foundation of China, Major Scientific Research Program for Young and Middle-aged Health Professionals of Fujian Province, China, Scientific Foundation of Fuzhou Municipal Health commission.
Abstract (Originalsprache)
Growing evidences have proved that tumors evade recognition and attack by the immune system through immune escape mechanisms, and PDL1/Pbrm1 genes have a strong correlation with poor response or resistance to immune checkpoint blockade (ICB) therapy. Herein, a multifunctional biomimetic nanocarrier (siRNA‐CaP@PD1‐NVs) is developed, which can not only enhance the cytotoxic activity of immune cells by blocking PD1/PDL1 axis, but also reduce tumor immune escape via Pbrm1/PDL1 gene silencing, leading to a significant improvement in tumor immunosuppressive microenvironment. Consequently, the nanocarrier promotes DC cell maturation, enhances the infiltration and activity of CD8+ T cells, and forms long‐term immune memory, which can effectively inhibit tumor growth or even eliminate tumors, and prevent tumor recurrence and metastasis. Overall, this study presents a powerful strategy for co‐delivery of siRNA drugs, immune adjuvant, and immune checkpoint inhibitors, and holds great promise for improving the effectiveness and safety of current immunotherapy regimens.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- The United Innovation of Mengchao Hepatobiliary Technology Key Laboratory of Fujian Province, Mengchao Hepatobiliary Hospital of Fujian Medical University, Fuzhou, 350025, P. R. China.
- Mengchao Med-X Center, Fuzhou University, Fuzhou, 350116, P. R. China.
- College of Biological Science and Engineering, Fuzhou University, Fuzhou, 350116, P. R. China.
- Liver Disease Center, The First Affiliated Hospital of Fujian Medical University, Fuzhou, 350005, P. R. China.
- CAS Key Laboratory of Design and Assembly of Functional Nanostructures, Fujian Institute of Research on the Structure of Matter Chinese Academy of Sciences, Fuzhou, 350002, P. R. China.
ORCID-Profile: Yongyi Zeng, Xiaolong Liu
Förderung
- National Natural Science Foundation of China
- Major Scientific Research Program for Young and Middle-aged Health Professionals of Fujian Province, China
- Scientific Foundation of Fuzhou Municipal Health commission
- Joint Funds for the Innovation of Science and Technology of Fujian Province
- Talent Training Project for the Innovation and Entrepreneurship of Science and Technology of Fuzhou city
Zitieren
APA
Sun, Y., Liu, Y., Li, R., Zhang, C., Wu, M., Zhang, X., Zheng, A., Liao, N., Zheng, Y., Xu, H., Zeng, R., Zeng, Y., & Liu, X. (2024). Multifunctional Biomimetic Nanocarriers for Dual‐Targeted Immuno‐Gene Therapy Against Hepatocellular Carcinoma. Advanced Science. https://doi.org/10.1002/advs.202400951
Vancouver
Sun Y, Liu Y, Li R, Zhang C, Wu M, Zhang X, et al. Multifunctional Biomimetic Nanocarriers for Dual‐Targeted Immuno‐Gene Therapy Against Hepatocellular Carcinoma. Advanced Science. 2024. doi:10.1002/advs.202400951
BibTeX
@article{Sun2024,
author = {Sun, Yupeng and Liu, Yan and Li, Rui and Zhang, Cuilin and Wu, Ming and Zhang, Xiaolong and Zheng, Aixian and Liao, Naishun and Zheng, Youshi and Xu, Haipo and Zeng, Rui and Zeng, Yongyi and Liu, Xiaolong},
title = {Multifunctional Biomimetic Nanocarriers for Dual‐Targeted Immuno‐Gene Therapy Against Hepatocellular Carcinoma},
journal = {Advanced Science},
year = {2024},
doi = {10.1002/advs.202400951}
}
EUVIMED